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Background: Crohn’s disease is an inﬂammatory disease that can reach any part of the
gastrointestinal tract. This disease has been associated with an increased neoplastic risk,
including colorectal carcinoma.
Objective: The objective of this work is to describe the mechanisms present in two diseases,
and  that are responsible for the increased risk in Crohn’s disease.
Methods: A bibliographic research was conducted in PubMed database. In addition to the
articles obtained with an inserted query in Pubmed, other references relevant to the topic
in  question were included.
Results: Colorectal cancer risk varies according to the presence of certain factors, and an
example of this is Crohn’s disease. Chronic inﬂammation seems to be an important con-
tribution to carcinogenesis, since it creates a microenvironment suitable for the onset and
progression of the disease. There are molecular changes that are common to two  conditions,
thus justifying the fact of Crohn’s disease being a risk factor for colorectal carcinoma. The
disease control with an appropriate therapy and with surveillance are two ways to control
this  risk.
Conclusions: A proinﬂammatory state is the cornerstone in the association between Crohn’s
disease and colorectal carcinoma. The implementation of surveillance strategies allowed a
decrease in morbidity and mortality associated with this cancer.
©  2016 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de
Coloproctologia. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Doenc¸a de  Crohn:  fator  de  risco  para  o  carcinoma  colorretal
r  e  s  u  m  oalavras-chave: Introduc¸ão: A doenc¸a de Crohn é uma doenc¸a inﬂamatória que pode atingir todo o trato
a patologia tem sido associada a um risco neoplásico aumentado,oenc¸a de crohn gastrointestinal. EstPlease cite this article in press as: Santos SC, Barbosa LE. Crohn’s disease: risk factor for colorectal cancer. J Coloproctol (Rio J). 2016.
http://dx.doi.org/10.1016/j.jcol.2016.06.005
arcinoma colorretal
nﬂamac¸ão
atores de risco
nomeadamente de carcinoma colorretal.
Objetivo: O objetivo deste trabalho é descrever os mecanismos responsáveis pelo aumento
do  risco de carcinoma colorretal na doenc¸a de Crohn.
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237-9363/© 2016 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Coloproctologia. This is an open access article
nder  the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ARTICLE IN PRESSJCOL-190; No. of Pages 8
2  j coloproctol (rio j). 2 0 1 6;x x x(x x):xxx–xxx
Métodos: A pesquisa bibliográﬁca foi realizada na base de dados Pubmed. Para além dos
artigos obtidos com a query inserida na Pubmed, foram também incluídas outras referências
com  relevância para o tema em questão.
Resultados: O risco de carcinoma colorretal aumenta na presenc¸a de determinados fatores,
entres eles a doenc¸a de Crohn. A inﬂamac¸ão crónica presente parece ser um importante
contributo para a carcinogénese, porque permite a criac¸ão de um microambiente adequado
ao  aparecimento e progressão da doenc¸a. Existem alterac¸ões moleculares comuns às duas
patologias justiﬁcando-se o fato desta doenc¸a inﬂamatória ser fator de risco para o carci-
noma colorretal. O controlo da doenc¸a com terapêutica adequada e estratégias de vigilâncias
são  duas formas de controlar o risco.
Conclusões: O estado pró-inﬂamatório é uma pec¸a chave na associac¸ão entre doenc¸a de
Crohn e carcinoma colorretal. A implementac¸ão de estratégias de vigilância permitiu a
diminuic¸ão  da morbi-mortalidade associada a esta neoplasia.
© 2016 Publicado por Elsevier Editora Ltda. em nome de Sociedade Brasileira de
Coloproctologia. Este e´ um artigo Open Access sob uma licenc¸a CC BY-NC-ND (http://Introduction
Inﬂammatory bowel diseases, of which Crohn’s disease (CD),
familial adenomatous polyposis, and the non-polypoid hered-
itary form are examples, are three diseases that confer a high
risk of colorectal carcinoma (CRC).1
CD is a chronic, progressive disease characterized by a pro-
inﬂammatory state. The quality of life of these patients is
affected substantially, although beneﬁts have occurred with
the appearance of various therapies.2,3
The multifactorial etiology of this disease is not fully
known, but some pathophysiological mechanisms underlying
it have been described.4
CD is characterized by chronic diarrhea (the symptom most
often present), weight loss, blood loss and abdominal pain. All
the gastrointestinal tract can be affected, and distal ileum and
colon are the parts most often affected.3–6
For the progression of this disease, genetic and environ-
mental factors and dysbiosis are contributing factors.2,3,7
About 2 million Americans and Europeans suffer from CD,
and its diagnosis is established mainly in the 2nd or 3rd decade
of life.7
CD may have intestinal and extra-intestinal manifesta-
tions, and the disease shows two predominant patterns.
According to the Montreal classiﬁcation, patients are catego-
rized according to their age at diagnosis, and disease location
and behavior. With regard to age at diagnosis, the categories
are ≤16 years, between 17 and 40 years, and ≥40 years.
The disease can be found in the ileum, colon, ileum-colon,
or upper gastrointestinal tract, showing a non-stenotic/non-
penetrating behavior, a stenotic behavior, or a penetrating
behavior.8
CRC arises due to a dysplasia of intestinal mucosa and is
more  common in these patients versus the general popula-
tion. Thus, this inﬂammatory disease is a risk factor for CRC
occurrence.5,9,10
CRC can cause death in these patients, and the diagnosisPlease cite this article in press as: Santos SC, Barbosa LE. Crohn’s dis
http://dx.doi.org/10.1016/j.jcol.2016.06.005
is rarely established before 7 years of disease progression.7,11
There is no consensus as to the quantiﬁcation of risk since
this is inﬂuenced by several factors.12creativecommons.org/licenses/by-nc-nd/4.0/).
The prognosis of CD varies from patient to patient, but
there are some factors which lead to a worse outcome,
including the perianal disease and the presence of upper gas-
trointestinal tract lesions, as well as an extensively affected
colon.
Material  and  methods
On July 6, 2015, a literature search in PubMed database was
performed with the following query ((“crohn’s disease” [MeSH
Terms] OR (“crohn” [All Fields] AND “disease” [All Fields]) OR
“crohn’s disease” [All Fields]) AND (“neoplasms” [MeSH Terms]
OR “neoplasms” [All ﬁelds] OR “cancer” [All Fields])). The inclu-
sion criteria were: studies published in the last 10 years and
articles written in Portuguese, English or Spanish. The titles
and abstracts were read, and 75 articles were selected.
On December 22, 2015, a new search was conducted with
the aim of updating the bibliography; the same query and
the same inclusion criteria used in the previous survey were
employed, and 48 articles were obtained.
Additional studies relevant to the issue in question were
also included, through a cross-search with the articles already
included, and a book relevant to the subject matter.
A total of 50 references were obtained.
Results
Epidemiology
Inﬂammatory bowel disease, which includes CD, is more
prevalent in developed countries; this leads one to think of
Westernization as a risk factor for this condition. Dietary
habits and lifestyle contribute in some way to its appearance.
One of the diagnostic peaks occurs in patients aged between
15 and 30 years, and 30% of patients are diagnosed under the
age of 20 years.13,14 The second peak occurs between 60 and
80 years, with a lower incidence versus the ﬁrst peak.15ease: risk factor for colorectal cancer. J Coloproctol (Rio J). 2016.
In CD, the inﬂammation occurs transmurally. The most
commonly affected locations are the terminal ileum and
colon. At the time of diagnosis, 40% of patients exhibit an
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leocolic location, 30% suffer from an isolated ileal disease,
nd 30% are affected only in the colon. Approximately 5–10%
f patients exhibit associated lesions of the upper gastroin-
estinal tract, and 20–30% show perianal disease.2
The control of the disease with medical therapy, partic-
larly with biological agents, constitutes an advantage for
hese patients; but despite the advances in science and in
harmacotherapy, the risk of complications involving bowel
esection remains in the range of 80%.12,16 Perianal lesions,
.e., ulcers, ﬁssures or ﬁstulas, are complications present in
0% of patients at diagnosis.5 Despite the medical therapeu-
ic efﬁcacy, the percentage of refractory patients spins around
5–30%. All these aspects contribute to an inadequate control
f the disease.7
CRC can arise in the context of CD, with a location in
reas of chronic inﬂammation. Regarding the quantiﬁcation
f risk, the results of the studies are mixed. Some studies
oint to a risk 2–3 times higher, while other studies cite a
isk six times higher. Each year, approximately 900,000 new
ases of CRC and 500,000 deaths occur worldwide. This cancer
ccounts for about 10–15% of deaths in patients with inﬂam-
atory bowel disease and the amount attributable to CD has
ot yet been determined.10,11,14,17 Other studies report that
 in 12 deaths of patients with Crohn’s disease is caused by
RC.1
The ﬁrst case of CRC related to CD was described in 1948,
nd since then the cause of this association is not yet fully
nderstood. In fact, the risk exists, but its magnitude has not
et been determined accurately.13
The incidence of CRC related to CD is variable, reaching
igher values in tertiary hospitals, where the inﬂammatory
isease attains more  severe stages.12
Studies related to this association found that there is a
umulative risk of CRC development. In evaluating a pop-
lation of Eastern Europe 20 years after the diagnosis, the
umulative risk was estimated at 1.1% (95% CI: 0.6–1.7%).
nother study found that the risk would be 2.9% after 10 years,
.6% after 20 years, and 8.3% after 30 years.13,18
The risk of cancer varies with the location of the disease.
hen the disease affects only the colon, the relative risk is 5.6,
hile in the case of ileocolic involvement, the relative risk is
.2; and studies in patients with extensive involvement of the
olon resulted in a calculated relative risk of 23.8.18
The presence of metachronous lesions is variable, ranging
rom a minimum value of 23% and a maximum of 70%.19
Basseri et al. conducted a study in which patients with
rohn’s disease were monitored for 17 years; these authors
ound a CRC development in 5.6% of the study population.18
Other studies have concluded that there was a decrease in
he incidence of CRC, but this ﬁnding can be explained by the
nset of medical therapies increasingly effective, appropriate
urgical treatment, and the existence of surveillance programs
hat allow an early detection of dysplasia.1
urveillancePlease cite this article in press as: Santos SC, Barbosa LE. Crohn’s dis
http://dx.doi.org/10.1016/j.jcol.2016.06.005
n association between an increased risk of CRC in a Crohn’s
atient exists, although the mechanisms responsible have not
et been fully elucidated.6 Thus, surveillance programs are of;x x x(x x):xxx–xxx 3
great importance and are aimed at reducing morbidity and
mortality.20,21
Given that one of the diagnostic peaks occurs between 15
and 30 years, the development of CRC associated with CD is
earlier than in the sporadic form, similar to what occurs in
patients with Lynch syndrome.10
Studies in patients with ulcerative colitis and CD revealed
a very similar cumulative frequency after 20 years (8% vs.
7%, respectively). According to the American Gastroenterology
Association (AGA), currently it is accepted that the risk of
developing CRC is equivalent in both pathologies, and it was
recommended that surveillance should begin eight years after
the diagnosis.22 The recommendations of the British Society
of Gastroenterology (BSG) are toward an onset of monitoring
about 10 years after diagnosis.6,10,21
However, in a study conducted in a tertiary hospital, two
cases of CRC with a one-year interval after the diagnosis of CD
were related; the remaining cases were reported at intervals
from 11 to 14 years.12 The prognosis of both types of CRC may
be more  favorable with an appropriate surveillance, consider-
ing that the neoplastic progression to more  advanced stages
will be avoided.10,18,23
In the case of establishing a diagnosis of primary scle-
rosing cholangitis (PSC), the surveillance should be started
immediately, being held annually in accordance with the rec-
ommendations of the AGA.22,24
The evolution from an inﬂamed to a dysplastic mucosa may
occur without macroscopically visible lesions, unlike what
happens in patients with sporadic CRC, that in about 70–80%
of cases follow the adenoma–carcinoma sequence.10,17,25,26
The lesions may be polypoid or ﬂat, multifocal or
unifocal.27 Some studies have raised doubts about the efﬁcacy
of the surveillance with colonoscopy, as ﬂat lesions are not
visible and may not be targeted sites of randomized biopsies.
The presence of dysplasia is a risk marker for carcinoma.17,25,27
When the lesions are macroscopically visible, should be tar-
geted for biopsy.28
In the case of ﬂat lesions, biopsies will be randomized,
not targeted; with this, one will count on a sample of only
0.03% of the mucosal surface of the colon. Therefore, if
a dysplastic area exists, and this area is not targeted for
a biopsy, cancer will progress and the diagnosis will be
delayed.29
There is no consensus among different organizations
and societies about surveillance strategies, which means
that there are different recommendations. The applica-
tion of surveillance strategies for all people with CD is
not a consensual procedure. Studies were published argu-
ing that surveillance should be carried out only for certain
subgroups. The deﬁnition of these subgroups is based on
factors that confer a greater risk of CRC, i.e., the extent
and duration of the disease, and also an extrapolation
from studies in patients with ulcerative colitis. Thus, these
studies maintain that surveillance should be applied only
to patients with a widely affected colon.30 Other authors
deﬁned more  speciﬁc conditions for surveillance recom-ease: risk factor for colorectal cancer. J Coloproctol (Rio J). 2016.
mendation, namely more  than 1/3 of the affected colon
and development of CD ≥ 8 years.21 These are the criteria
adopted by AGA to deﬁne which patients should undergo
surveillance.22
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According to AGA, biopsies at every 10 cm (min: 33) shall
be obtained.21,24,29 Undeﬁned results are an indication for a
repeat examination after 3–6 months. The presence of high-
grade dysplasia is an indication for colectomy. Therefore,
the histological results deﬁne which procedure to perform:
Surveillance colonoscopy, or surgical treatment.18,28,31
AGA recommends conducting surveillance at intervals of
1–3 years, and never exceeding 8 years after diagnosis.3,24,32
In the case of a positive family history for CRC in 1st-degree
relatives, active inﬂammation and anatomical changes, for
example, stenosis, monitoring intervals should be shorter.22
BSG recommends that the colonoscopy should be carried out
at intervals of 3 or 5 years, taking into account the underlying
risk factors after 10 years.3,32,33
As already mentioned, metachronous lesions may occur
in a signiﬁcant percentage of patients. Thus, dysplasia can
be detected in more  than one biopsy, and in more  than one
location.31
The surveillance must be carried out in periods of remis-
sion unless in the case of a long-standing inﬂammation.22
The evolution of technology has allowed the use of chro-
moendoscopy instead of randomized biopsies; by this method,
the biopsies are directed, allowing greater efﬁciency in detec-
ting dysplasia.6
The chromoendoscopy allows the enhancement of dys-
plastic areas through light ﬁlters, or through agents such as
methylene blue and indigo carmine.29,34
This type of endoscopy is recommended by various enti-
ties for the monitoring of patients at increased risk of CRC,
for example, patients with CD.34,35 This diagnostic method
allows an increase of 7% (95% CI: 3.2–11.3) in the detection
of dysplasia versus white light endoscopy; but it remains
to be seen what is its degree of technical inﬂuence on
patient survival. Despite this uncertainty, the SCENIC con-
sensus statement (Surveillance for Colorectal Endoscopic
Neoplasia Detection and Management in Inﬂammatory Bowel
Disease Patients: International Consensus Recommendations)
recommends chromoendoscopy as a technique of choice for
monitoring dysplastic areas in patients with CD.3 BSG also
recommends chromoendoscopy as a monitoring method for
all patients; but if this technique is not available, 2–4 biopsies
every 10 cm should be obtained.22,29 On the other hand, AGA
recommends chromoendoscopy only in special cases.29
Techniques such as ﬂow cytometry, immunohistochem-
istry, marker survey are essential to conﬁrm the diagnosis of
cancer.4
Neoplastic biomarkers can also be another way to detect or
conﬁrm the presence of cancer; however, they are not part of
the surveillance strategies.12
The progress of anti-inﬂammatory therapy for CD and a
proper monitoring of these patients have improved the diag-
nosis of CRC and increased survival.17 Thus, surveillance
strategies are an important way to improve the prognosis of
these patients. Early diagnosis ensures a tumor detection in
less advanced stages; thus, most frequently the treatment has
a curative effect.36
The surveillance has proved to be a powerful weapon inPlease cite this article in press as: Santos SC, Barbosa LE. Crohn’s dis
http://dx.doi.org/10.1016/j.jcol.2016.06.005
the ﬁght against CRC, since the presence of symptoms can
be nonspeciﬁc, perhaps implying difﬁculty with a diagnosis
based only on clinical ﬁndings.376;x x x(x x):xxx–xxx
Molecular  changes
CRC development in patients with CD seems to be due to an
interaction between genetic and acquired factors. The interac-
tion between inﬂammation and regulatory genes of neoplastic
pathways appears to play an important role in tumorigenesis.
Some authors argue that the contribution from inﬂamma-
tion is more  signiﬁcant than the contribution of the genetic
component.18,25,27 Changes can occur in oncogenes, tumor
suppressor genes (i.e., p53), and genes of DNA repair (MLH1,
MSH2, MSH6).18
The genetic alterations are present even before the occur-
rence of histological alterations of the mucosa.27
The ﬁrst genetic change related to CD was in NOD2/CARD15
(nucleotide-binding oligomerization domain containing
2/caspase recruitment domain-containing protein 15), which
ultimately increases the production of pro-inﬂammatory
cytokines. NOD2 protein is an intracellular sensor of bacterial
peptidoglycans, which will act via nuclear factor kappa B
(NF-kB).14,38 Thus, this genetic change helps to perpetuate
inﬂammation, being indirectly related to carcinogenesis.14
Pro-inﬂammatory factors play an important role in the
development and evolution of CD, and there may also be
changes in their genes. One of the altered genes can be
the tumor necrosis factor  (TNF-),  which is located on
chromosome 6. Polymorphisms occurring in the promoter
region of this gene can alter cytokine production; thus,
they can increase the susceptibility to conditions related to
inﬂammation.39 Thus, TNF- contributes to inﬂammation in
patients with CD, not only being involved in tumor prolif-
eration, but also in the metastatic process. This factor is
associated with an increased expression of cyclooxygenase-2
(COX-2), cell proliferation, and angiogenesis.7
The presence of a mutation in the tumor suppressor gene
p53 in differs in sporadic cases and in cases associated with
CD. In the ﬁrst situation, the mutation is present in advanced
stages; however, in this latter situation the mutation may be
present in the non-dysplastic mucosa.10,27
Mutations in E-cadherin gene are one type of genetic
change present in some cases. These mutations have been
associated with the occurrence of cancer, i.e., gastric carci-
noma; it is believed that this may be one of the mechanisms
of carcinogenesis in CD.
Several studies have concluded that micro-RNAs (MIR) are
involved in the pathophysiology of CD and CRC, and may
be a key link in the relation of these two diseases. MIR  may
constitute early biomarkers of colon cancer and may also be
important in the detection and prevention of breast cancer.
Two types of MIR  were described: those promoting tumor sur-
vival and growth (onco-micro-RNA) and those which suppress
neoplastic progression (micro-RNA tumor suppressor). The
second type of MIR, above mentioned, is that that is most often
related to tumorigenesis, and the mechanism underlying this
situation is the retardation of its activity. MIR deregulation that
exacerbates existing inﬂammation in CD may increase the risk
of CRC in patients who already exhibit a somatic mutation.
From the above, one can conclude again that the relationshipease: risk factor for colorectal cancer. J Coloproctol (Rio J). 2016.
between these disorders includes the interaction of several
factors. One of the mechanisms by which MIR  exacerbate the
inﬂammation is the interaction with COX-2. MIR-26b has only
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ne binding site located within the non-transcribed 3′ zone
f this enzyme, thus allowing its direct connection with the
nﬂammatory process.37
MIR-191 has also been associated with CD and CRC, dis-
ases in which it shows an aberrant expression. In the case of
RC, MIR-191 levels may be increased or decreased. In most
ases the levels are high, and the cases described with low
evels are associated with a worse prognosis. In the case of
D, MIR-191 may also be changed, and apparently regulating
nnate and acquired immunity.40
Autophagy seems to be another connecting link, acting as
 tumor suppressor.7,14 The gene for autophagy, ATG16L1, can
e changed.38 During tumorigenesis, autophagy is negatively
egulated by several genes. Defects in autophagy have been
ssociated with several pathologies, including CD and CRC.14
Oxidative stress and its underlying damage are changes
hat are present in CD and perhaps contributing to tumori-
enesis. In the case of CD, an increase of reactive oxygen
nd nitrogen reactive species occurs, which in turn lead
o alterations in DNA, RNA, proteins, and lipids.23,41 These
enetic alterations that affect the immune system have been
escribed in these two diseases, with an involvement of innate
nd acquired immunity.23,27 the result of these changes may
e the loss of function of tumor suppressor genes, a gain of
unction of oncogenes, or loss of genetic stability.11
nﬂammation
D is a condition in which, it is believed, non-pathogenic
ommensal bacteria trigger an unregulated immune response
gainst the mucosa, whose function is to serve as a barrier.42
Chronic inﬂammation is related to tissue damage and to
he recruitment of immune system cells that act to perpetu-
te inﬂammation. There is also a rapid renewal of the colonic
ucosa, which increases the risk of DNA damage.11
Inﬂammation is a very important feature in CD, and sev-
ral studies show that the increased neoplastic risk is due
o their persistence, taking into account that the association
etween cancer and inﬂammation has been established.18,20
hus, the risk is substantially larger in situations where
he control of the inﬂammatory response is inappropriate.43
he presence of pro-inﬂammatory cytokines carries a perma-
ent pro-inﬂammatory state which increases the neoplastic
isk.18,25
Inﬂammation promotes the creation of a suitable microen-
ironment for neoplastic formation and progression. Several
echanisms contribute to the development of this microen-
ironment.
The expression of some genes related to inﬂammation is
ncreased in mucosa of these patients, particularly COX-2.11
he induction of this enzyme occurs thanks to the acti-
ation of toll-like receptor-4 (TLR-4) and to the increased
roduction of proinﬂammatory cytokines by immune system
ells.7,23 This signaling pathway will lead to the pro-
uction of prostaglandins in epithelial cells which, along
ith local cytokines, inhibit apoptosis, thereby favoring
23Please cite this article in press as: Santos SC, Barbosa LE. Crohn’s dis
http://dx.doi.org/10.1016/j.jcol.2016.06.005
arcinogenesis. The induction of COX-2 has another impor-
ant consequence–the decrease of unesteriﬁed arachidonic
cid. The importance of this fact lies in the pro-apoptotic func-
ion of this acid. In cases in which the acid is decreased, the;x x x(x x):xxx–xxx 5
apoptosis process also will be decreased, which promotes cell
proliferation.23
Aside TLR, there are other receptors that contribute to
inﬂammation, the NOD-like receptors (NLRs). The ﬁrst genetic
change related to CD occurred precisely in one of these recep-
tors, NOD-2. This receptor and NOD-1 contribute signiﬁcantly
to inﬂammation at the intestinal level. NOD-1 and NOD-2 rec-
ognize molecules, particularly bacterial peptidoglycans, which
penetrate into cells by various processes, for example by
phagocytosis. The binding of the peptidoglycans to NLRs acti-
vates pro-inﬂammatory and anti-microbial molecules. NLRs,
in collaboration with TLRs, allow the detection of bacteria and
activation of pro-inﬂammatory mechanisms.44
Rodent studies have concluded that the deﬁciency of trans-
forming growth factor beta (TGF-), exacerbates the activation
of NF-kB and the secretion of proinﬂammatory cytokines,
which protect cells from apoptosis.7,41
In patients with CD, in addition to changes in pro-
inﬂammatory factors, alterations in cellular immunity also
occur. The change of T cell phenotype is closely linked to the
regulation of inﬂammation in CD as well as to related can-
cer; however, the results of previously published studies are
contradictory.43,45 Regulatory T cells are a major intervening
factor in the inﬂammatory process. An inappropriate response
to the microﬂora plays an important role in the pathogenesis
of CD. In this inﬂammatory disease, there is a change in the
balance between regulatory T cells in the blood and in the
inﬂamed site in the bowel and, in addition, there is an excess
of pro-inﬂammatory stimuli.18,27 However, if on one hand it is
believed that the regulatory T cells are important in control-
ling inﬂammation in CD and, therefore, have a protective role,
on the other hand, it is known that, in the initial process of
carcinogenesis, these cells suppress anti-tumor mechanisms,
promoting neoplastic progression.
Studies in rodents showed that inﬂammation, in addition
to its local role at bowel level, also acts at a distance, inducing
thymic involution and therefore a change (i.e., a decrease) in
the production of T cells. This suppression means that there
will be less control of inﬂammation.43
Smoking can also be detrimental to the progress of the dis-
ease by altering the gene expression and by contributing to
inﬂammation. Thus, in smokers the progression of the disease
tends to be more  severe.12,38,46
Risk  factors  for  colorectal  carcinoma  in  patients  with  CD
The risk factors for CRC development are family history of CRC,
the extent of the injury, disease duration, primary sclerosing
cholangitis (PSC), histologic characteristics, disease pheno-
type and age at the time of diagnosis.12,23,30,47
The risk can be mitigated by an appropriate surveillance
and surgical treatment when necessary.12
The gender of the patient is not considered a risk factor,
and there is a disparity between the results. There are studies
indicating that the difference is not signiﬁcant. However, other
authors found results that point to an increased incidence in
6,13ease: risk factor for colorectal cancer. J Coloproctol (Rio J). 2016.
men.
A family history of CRC is an important factor that doubles
the risk.24 A study concluded that the risk of CRC in patients
with CD and with a history of 1st-degree relatives with this
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cancer is 3.7 times higher versus patients with no such fam-
ily history.11,14 However, it is important to note that having a
family member with DC does not increase the risk of CRC.23
it is evident that family history is an independent risk factor,
but is an indication for smaller surveillance intervals.24
The risk of CRC is naturally higher in patients with exten-
sive lesions in the colon.1,30,31 is also known that, in many
cases, cancer occurs along ﬁssures and ﬁstulas.30,31
A diagnosis established at an early age and the presence of
active inﬂammation also represent risk factors, as discussed
above. Studies have concluded that if the diagnosis is made
before the age of 30 years, the relative risk shows a consider-
able increase.11,23,48
The association between CD and PSC has been known
since 1964. The coexistence of these diseases constitutes a
summation with respect to CRC risk, with a contribution of
inﬂammation in CD, and of the high concentrations of bile
acids in the colon, secondary to cholangitis.10 PSC is present
in 1–3% of patients with CD, but there is no certainty about the
actual risk of CRC in patients with both pathologies.1
Phenotypic presentation in the form of stenosis can also
affect the risk of developing CRC. Studies indicate an increased
risk when the disease is stenotic.13,30
With the medical therapy used in the treatment, the patient
can be kept in remission for long periods of time; thus, surgery
is avoided.6,16,49 The role of thiopurines in the risk of CRC is
controversial. The purpose of using these drugs is the reduc-
tion of inﬂammation; therefore, its use should decrease the
risk of CRC. However, one of the effects of immunosuppressive
drugs is a greater neoplastic risk. In fact, thiopurines increase
the risk of some cancers, including skin cancers and lym-
phomas, but because of its anti-inﬂammatory effect, the use of
this drug seems to contribute to a decreased risk of colorectal
neoplasia. In parallel, non-steroidal anti-inﬂammatory drugs
also appear to lower the risk.6,16
CRC associated with CD develops mostly in young peo-
ple and it appears to be a more  diffuse, extensive, multifocal
and mucinous disease when compared with sporadic CRC.
This cancer usually appears on the right side, and this is
related to the known higher frequency of inﬂammation at this
location.12,18
Discussion
An increase in the risk of CRC in patients with CD is a fact,
despite the still incomplete knowledge of the mechanisms
involved.
The value of the relative risk varies in different studies
since this variable depends on several factors. The heterogene-
ity in the methodology observed in several studies complicates
the comparison of results.
A decrease in the risk of CRC has been described; it is likely
that this is due to improved surveillance methods, with the
possibility of increasing early diagnoses.Please cite this article in press as: Santos SC, Barbosa LE. Crohn’s dis
http://dx.doi.org/10.1016/j.jcol.2016.06.005
The monitoring of these patients is aimed not only to con-
trol the inﬂammation of the underlying disease, but also to
avoid CRC. Obtaining directed biopsies by chromoendoscopy
is the most effective method; this enables a higher percentage6;x x x(x x):xxx–xxx
of dysplasia detection, considering that most of the lesions are
not visible by conventional colonoscopy.
In most studies, the interval from diagnosis of CD to the
diagnosis of CRC was about 10 years. However, two cases of
CRC, whose diagnosis was established one year after the onset
of symptoms were related. The diagnosis of CRC may occur
even before the diagnosis of CD.12,45 In these situations, the
CRC appears to be an independent event CD.
The increased risk may also be explained by the fact that
the genetic changes that lead to the emergence of CD can also
contribute to the onset of CRC.12
The presence of an affected colon entails increased risk
because the underlying inﬂammation may contribute to car-
cinogenesis.
Regarding the intervening factors, some argue that the age
of diagnosis cannot be considered as a true risk factor. These
authors argue that the risk is related to the duration of the dis-
ease. Early diagnoses allow one to conclude that for the same
age, such patients have a longer duration of the disease.23
In the case of a CRC diagnosis in a patient with CD, it is
important to distinguish whether the carcinoma is sporadic,
whether it is associated with the inﬂammatory disease, or
whether it is a case of Lynch syndrome. This is particularly
relevant as it will inﬂuence the treatment offered, consist-
ing in total colectomy in cases where the diagnosis of CRC
is associated with CD or Lynch syndrome. The distinction can
be performed based on the patient’s MIR proﬁle. In patients
with Lynch syndrome, there is an increased expression of MIRs
16–2 and 30-a, while in those suffering from CD there is an
increased expression of MIRs 191, 23b and 16.32,37
MIRs play an important role in CD and CRC, but there is a
need for further studies so that one can be able to establish the
actual diagnostic and prognostic value of such substances.
Conclusion
Inﬂammation is a key element in the association between CD
and CRC, and its control decreases the risk of carcinogenesis.
The pro-inﬂammatory state and molecular changes that occur
partly explain the neoplastic risk underlying to this inﬂamma-
tory disease.
Regarding CD, there are risk factors, in particular, the dura-
tion of disease (an already well-studied variable for ulcerative
colitis, and now applied to CD) and the extent of colonic
involvement.
Surveillance has become an increasingly important fea-
ture. In some cases, the conventional colonoscopy does not
establish a diagnosis, and the appearance of chromoen-
doscopy increased the detection of a dysplastic mucosa. In
those cases in which such a change is detected, the recom-
mendation is to perform a complete colectomy.
Immunosuppression, along with the pro-inﬂammatory
state, may explain this association although non-steroidal
anti-inﬂammatory agents appear to delay the onset of cancer.ease: risk factor for colorectal cancer. J Coloproctol (Rio J). 2016.
The role of immunosuppression is controversial since studies
have been published with different conclusions.
The use of appropriate surveillance protocols allows an
early detection of the onset of cancer, and this translates into
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